ARWR vs VNO · rev $829.4M vs rev $921.3M
Arrowhead Pharmaceuticals Inc (ARWR) versus VNO (VNO) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
VNO (VNO) common stock.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported VNO revenue for 2026-06-30 was $921.3M. Net income was $24.6M. VNO currently screens at market cap $0.
ARWR currently screens at market cap $10.59B. VNO currently screens at market cap $0.
Not investment advice. Open the ARWR and VNO stock pages for the full models.
Not investment advice.